148256-82-0

Usage

Uses

Used in Pharmaceutical Industry:
4-Chloro-2-(methylthio)pyrimidine-5-carboxaldehyde is used as a key intermediate for the synthesis of anticancer and antiviral drugs. Its unique structure and reactive aldehyde group enable the development of new therapeutic agents with potential applications in treating various diseases.
Used in Agrochemical Industry:
In the agrochemical industry, 4-Chloro-2-(methylthio)pyrimidine-5-carboxaldehyde is used as a building block in the preparation of diverse heterocyclic compounds. These compounds can be further utilized in the development of new agrochemicals, such as pesticides and herbicides, to improve crop protection and yield.
Used in Organic Chemistry:
4-Chloro-2-(methylthio)pyrimidine-5-carboxaldehyde is a versatile and important reagent in organic chemistry. Its unique structure and functional groups make it suitable for various organic reactions, such as condensation, substitution, and reduction, leading to the formation of a wide range of organic compounds with diverse applications.

Upstream product

• 74840-34-9 4-chloro-2-(methylsulfanyl)pyrimidine-5-carboxylic acid 
• 5909-24-0 4-chloro-2-methanesulfanylpyrimidine-5-carboxylic acid ethyl ester 
• 1044145-59-6 [4-chloro-2-(methylsulfanyl)pyrimidin-5-yl]methanol 
• 49844-90-8 4-Chloro-2-methylthiopyrimidine 

Downstream Products

• 55084-74-7 6-methylsulfanyl-1⁽²⁾H-pyrazolo[3,4-d]pyrimidine 
• 1192310-21-6 6-(2-chloro-5-nitrophenyl)-8-methoxy-2-(methylthio)pyrido[2,3-d]pyrimidin-7(8H)-one 
• 1192310-20-5 (Z)-6-(2-chloro-5-nitrophenyl)-2-(methylthio)-7H-pyrano[2,3-d]pyrimidin-7-one O-methyl oxime 
• 1192310-27-2 6-(2-chloro-4-nitrophenyl)-8-methoxy-2-(methylthio)pyrido[2,3-d]pyrimidin-7(8H)-one 
• 1192310-26-1 (Z)-6-(2-chloro-4-nitrophenyl)-2-(methylthio)-7H-pyrano[2,3-d]pyrimidin-7-one O-methyl oxime 
• 1192309-52-6 1-{4-Chloro-3-[2-(2-dimethylamino-ethylamino)-8-methoxy-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl]-phenyl}-3-(3-chloro-4-methoxy-phenyl)-urea 
• 1192310-22-7 6-(2-chloro-5-nitrophenyl)-8-methoxy-2-(methylsulfonyl)pyrido[2,3-d]pyrimidin-7(8H)-one 
• 1192310-23-8 6-(2-chloro-5-nitrophenyl)-2-(2-(dimethylamino)ethylamino)-8-methoxypyrido[2,3-d]pyrimidin-7(8H)-one 
• 1192310-18-1 6-(5-amino-2-chlorophenyl)-2-(2-(dimethylamino)ethylamino)-8-methoxypyrido[2,3-d]pyrimidin-7(8H)-one 
• 1192310-28-3 6-(2-chloro-4-nitrophenyl)-8-methoxy-2-(methylsulfonyl)pyrido[2,3-d]pyrimidin-7(8H)-one 
• 1192310-29-4 6-(2-chloro-4-nitrophenyl)-2-(2-(dimethylamino)ethylamino)-8-methoxypyrido[2,3-d]pyrimidin-7(8H)-one 
• 1192310-24-9 6-(4-amino-2-chlorophenyl)-2-(2-(dimethylamino)ethylamino)-8-methoxypyrido[2,3-d]pyrimidin-7(8H)-one 
• 1021303-31-0 6-(2-chlorophenyl)-8-(1,1-dimethyl)ethyloxy-2-phenylaminopyrido[2,3-d]pyrimidin-7-one 
• 1021303-33-2 6-(2-chlorophenyl)-8-(1-methylethyl)oxy-2-phenylaminopyrido[2,3-d]pyrimidin-7-one 

Relevant academic research and scientific papers

Synthetic route of generic FGFR covalent inhibitor PRN1371

The invention relates to a synthetic route of a generic FGFR covalent inhibitor PRN1371, and belongs to the field of medicinal chemistry. The synthetic route steps of the PRN1371 comprise 11 steps, purification of a product can be achieved through simple operation of various intermediates in the aftertreatment process, the problems that the product is difficult to separate, the purification operation yield is low and the like are solved, and industrial production is facilitated. The invention aims to provide a synthetic route of the FGFR irreversible covalent inhibitor PRN1371, and the methodhas the advantages of few synthesis steps, simple operation, high yield, reduction of the production cost, and provision of a new synthesis idea for the industrial production of PRN1371.

2-Oxo-3,4-dihydropyrimido[4,5-d] pyrimidines as new reversible inhibitors of EGFR C797S (Cys797 to Ser797) mutant

Extensive structure-activity relationships (SARs) study of JND3229 was conducted to yield a series of new reversible 2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidine privileged scaffold as EGFRC797S inhibitors. One of the most potent compound 6i potently suppressed EGFRL858R/T790M/C797S kinase with an IC50 value of 3.1 nmol/L, and inhibited the proliferation of BaF3 cells harboring EGFRL858R/T790M/C797S and EGFR19D/T790M/C797S mutants with IC50 values of 290 nmol/L and 316 nmol/L, respectively. Further, 6i dose-dependently induced suppression of the phosphorylation of EGFRL858R/T790M/C797S and EGFR19D/T790M/C797S in BaF3 cells. Compound 6i may serve as a promising lead compound for further drug discovery overcoming the acquired resistance of non-small cell lung cancer (NSCLC) patients.

BENZAMIDES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF

Provided is a novel class of orally and/or topically available, selective and potent JAK inhibitors as safe and effective therapeutics against various diseases and disorders. More particularly, provided are pharmaceutical composition of these compounds and methods of their preparation and use thereof.

CYCLIN-DEPENDENT KINASE INHIBITORS

Described herein are compounds and their pharmaceutically acceptable salts, pharmaceutical compositions thereof, methods of treatment, and medical uses. The compounds described herein are modulators of cyclin-dependent kinases, and are useful in the treatment or alleviation of protein kinase associated disorders, including cancer, infectious diseases, autoimmune diseases, or cardiovascular diseases.

Synthetic method of cyclopentyl pyrimido pyrroles compound

The invention discloses a synthetic method of a cyclopentyl pyrimido pyrroles compound, which belongs to the field of organic chemical synthesis. Through steps of reduction, oxidation, aldol condensation, aminolysis and nucleophilic substitution, the cyclopentyl pyrimido pyrroles compound is synthesized. The raw materials have the advantages of low cost and easy acquisition, a related intermediate is easily separated and purified, operation is simple, the method is friendly to environment, the purity of the product is high, and the product has good industrial prospect. The prepared cyclopentyl pyrimido pyrroles compound, especially 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazine-1-yl)pyridine-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-methanamide has inhibition effect on cyclin-dependent kinase CDK4/6, and has good clinical treatment effect on melanoma and breast cancer.

SERINE/THREONINE KINASE INHIBITORS

Compounds having the formula I wherein R1, R2, R3, R4, R5, Ra, Rb, Rc, Rd, Re, n, r, s and t are as defined herein and which compounds are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders.

Design of Selective PAK1 Inhibitor G-5555: Improving Properties by Employing an Unorthodox Low-pKa Polar Moiety

Signaling pathways intersecting with the p21-activated kinases (PAKs) play important roles in tumorigenesis and cancer progression. By recognizing that the limitations of FRAX1036 (1) were chiefly associated with the highly basic amine it contained, we devised a mitigation strategy to address several issues such as hERG activity. The 5-amino-1,3-dioxanyl moiety was identified as an effective means of reducing pKa and logP simultaneously. When positioned properly within the scaffold, this group conferred several benefits including potency, pharmacokinetics, and selectivity. Mouse xenograft PK/PD studies were carried out using an advanced compound, G-5555 (12), derived from this approach. These studies concluded that dose-dependent pathway modulation was achievable and paves the way for further in vivo investigations of PAK1 function in cancer and other diseases.

TRICYCLIC LACTAMS FOR USE IN THE PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY

This invention is in the area of tricyclic lactam compounds, compositions and methods of protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents. In one aspect, protection of healthy cells is disclosed using compounds that act as cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects undergoing DNA damaging chemotherapeutic regimens for the treatment of proliferative disorders.

NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITION AND METHODS THEREOF

Disclosed are novel heteroaryl and heterocycle compounds of formula I-1, I-2 or I-3 and pharmaceutical compositions comprising them, uses and methods thereof for inhibiting the activity of PI3K and for treating inflammatory and autoimmune diseases and cancer.

NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITIONS AND METHODS

Provided are novel heteroaryl and heterocycle compounds of formula (I-1), (I-2) or (I-3) and pharmaceutical compositions comprising them, uses and methods thereof for inhibiting the activity of PI3K and for treating inflammatory and autoimmune disorders diseases and cancer.